0.0975GBp0.00%Mkt Cap: 25.27M GBpP/E: —Last update: 2026-05-13
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, a…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)51.59
PEG—
P/B2.71
P/S5.45
EV/EBITDA-26.19
EV/Revenue4.62
EPS (TTM)0.00
EPS (Forward)0.00
Cash Flow & Leverage
FCF Yield-6.41%
FCF Margin-34.90%
Operating CF-1.24M GBp
CapEx (TTM)158.83K GBp
Net Debt/EBITDA4.62
Net Debt-3.79M GBp
Technical
SMA 503.513 (-97.2%)
SMA 20012.36 (-99.2%)
Beta0.13
S&P 52W Chg24.23%
Avg Vol (30d)248.97K
Avg Vol (10d)0
Technical Indicators
RSI (14)24.1
MACD-1.2955
MACD Signal-1.6706
MACD Hist.+0.3750
BB Upper0.0975 GBp
BB Middle0.0975 GBp
BB Lower0.0975 GBp
BB Width0.00%
ATR (14)0.3604 GBp
Vol Ratio (20d)—
52W Range
0.09750% of range23.00
52W High23.00 GBp
52W Low0.0975 GBp
Profitability
Gross Margin61.65%
EBITDA Margin-17.65%
Profit Margin-15.01%
Oper. Margin-2.86%
ROE-7.39%
ROA-5.74%
Revenue Growth177.80%
Earnings Growth—
Balance Sheet
Debt/Equity0.11
Current Ratio4.84
Quick Ratio4.21
Book Value/Sh0.0360 GBp
Cash/Share0.0180 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.259.17M
Float147.81M
Insiders38.85%
Institutions14.31%
Analyst Consensus
Rating—
Target (Mean)29.00 GBp
Target Range29.00 GBp – 29.00 GBp
# Analysts1
Company
Market Cap25.27M GBp
Enterprise Value21.45M GBp
Revenue (TTM)4.64M GBp
Gross Profit2.86M GBp
Net Income (TTM)-696.25K GBp
Revenue/Share0.0200 GBp
Fiscal Year EndJun 2025
MR QuarterJun 2025
Employees41
Last Price0.0975 GBp
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—